TFBS Bioscience Inc.
TFBS Bioscience Inc., a contract research organization, provides biological testing services in Taiwan. It offers viral vector manufacturing services for cell and gene therapy products; and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products. The company was incorporated in 2016 and is headquartered in New Taipei City, Taiwan.
TFBS Bioscience Inc. (6939) - Total Liabilities
Latest total liabilities as of June 2025: NT$328.92 Million TWD
Based on the latest financial reports, TFBS Bioscience Inc. (6939) has total liabilities worth NT$328.92 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TFBS Bioscience Inc. - Total Liabilities Trend (2020–2024)
This chart illustrates how TFBS Bioscience Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TFBS Bioscience Inc. Competitors by Total Liabilities
The table below lists competitors of TFBS Bioscience Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Psyence Biomedical Ltd. Warrant
NASDAQ:PBMWW
|
USA | $943.07K |
|
BKK LIFE ASSUR NVDR
MU:XBLA
|
Germany | €260.78 Billion |
|
SINOTRANS -H-
MU:SIY
|
Germany | €36.56 Billion |
|
Kooth plc
LSE:KOO
|
UK | GBX7.80 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down TFBS Bioscience Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TFBS Bioscience Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TFBS Bioscience Inc. (2020–2024)
The table below shows the annual total liabilities of TFBS Bioscience Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$265.14 Million | +41.45% |
| 2023-12-31 | NT$187.44 Million | +48.54% |
| 2022-12-31 | NT$126.18 Million | +89.94% |
| 2021-12-31 | NT$66.44 Million | +64.41% |
| 2020-12-31 | NT$40.41 Million | -- |